GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx has been one of the victims of the fear, uncertainty and doubt currently being propagated in the digital healthcare realm. According to the market presently, there's something of a mutually-assured destruction agreement among players such as GoodRx, Teladoc, Hims & Hers Health, and Amazon.

GoodRx: The Good Doctor Has Come To Deliver Market-Beating Returns

Accolade

American Well Corporation

Teladoc

SOC Telemed

To make the most of the booming telehealth industry, players are coming up with IPOs and resorting to mergers and acquisitions.

Booming Telehealth Market Lures More IPOs and M&A Deals

GoodRx has been hit hard along with large tech stocks, along with other worries about Amazon.

GoodRx: A Battered Stock With Tremendous Upside

This consumer healthcare platform went public last fall and is looking to shake up a big part of the healthcare industry.

Is Now the Time to Buy This Pharma Industry Disruptor?

The market is wondering what to make of GoodRx after a mixed earnings report last week. Q1 revenue was up 20 percent, rising to $160.4 million from $133.4 million a year earlier.

GoodRx Picks Its Battles With Amazon And Healthcare Costs

The shares of GoodRx Holdings Inc (NASDAQ: GDRX) have received a price target decrease from $56 to $50 by RBC Capital. These are the details.

GoodRx (GDRX) Stock: $50 Target By RBC Capital

"We're transitioning from the Covid crisis into the other health-care crisis" of affordability, GoodRx co-CEO Doug Hirsch told CNBC.

GoodRx co-CEO touts recent acquisitions, says its business is 'rock solid' and only getting better

GoodRx Holdings, Inc. (GDRX) Q1 2021 Results - Earnings Call Transcript

Discount drug broker GoodRx is acquiring its competitor RxSaver, which is owned by marketing firm Vericast, in a $50 million deal, Bloomberg reported, citing sources. Controlled by billionaire investor Ronald Perelman, who also controls Vericast, RxSaver was sold off to GoodRx last month, investors were told on a private call on Thursday (May 13), the […]

GoodRx To Acquire RxSaver In $50 Million Deal

Shares of GoodRX Holdings Inc. fell more than 5% in the extended session Thursday after the health-care company reported first-quarter sales slightly below Wall Street expectations and met the forecast for adjusted profit. GoodRx said it earned $1.7 million, breaking even on a per-share basis, in the quarter, compared with $27.3 million, or 8 cents a share, in the year-ago quarter.

GoodRx stock heads lower after mixed Q1 results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), America's leading resource for healthcare savings, has released its first quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will host a conference call and webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. First Quarter 2021 R

GoodRx Releases First Quarter 2021 Financial Results

GoodRx' (GDRX) manufacturer solutions offerings continue to grow at a strong rate, registering record bookings over the past months.

GoodRx (GDRX) to Report Q1 Earnings: What's in the Offing?

SAN DIEGO & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $GDRX #ClassAction--Shareholder rights law firm Robbins LLP is investigating GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of shareholders to determine whether certain GoodRx officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. GoodRx is a holding company that owns and operates a U.S. consumer-focused digital healthcare platform. If you suffered a loss due to GoodRx Holdings, Inc.'s misconduct, cl

Shareholder Alert: Robbins LLP is Investigating GoodRx Holdings, Inc. (GDRX) on Behalf of Shareholders

Apollo Medical Hlds

Avantor Inc.

COMPASS Pathways

5 Top Medical Services Stocks to Beat COVID-Led Industry Challenges

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), America's leading resource for healthcare savings, today announced an integrated offering with global biopharmaceutical company Sanofi (Nasdaq: SNY) to streamline patient access to Sanofi discounts. Commercially insured and uninsured patients can now find, apply for, and claim Sanofi manufacturer discounts directly on the GoodRx platform. This integration makes it easier for the millions of people living with diabetes to access insul

GoodRx Announces Streamlined Access to Sanofi Savings Programs

Alibaba

DoorDash

Lemonade

Palantir Technologies

QuantumScape

Virgin Galactic

Even with the recent selling, many growth stocks are still fetching hefty valuations. The post 7 Growth Stocks That May Be Running Out of Steam appeared first on InvestorPlace.

7 Growth Stocks That May Be Running Out of Steam

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, Inc. (NASDAQ: GDRX), America's leading resource for healthcare savings, today announced the closing of the acquisition of HealthiNation as part of the company's continued investment in vital health information and consumer resources to help Americans navigate the complex world of healthcare. HealthiNation offers a comprehensive library of thousands of premium videos on a wide range of health topics that provide a platform for pharmaceutical manufac

GoodRx Expands Manufacturer Solutions Offering with Acquisition of HealthiNation

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), America's leading resource for healthcare savings, today announced it will release its first quarter 2021 financial results after U.S. markets close on Thursday, May 13, 2021. GoodRx management will hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. Prior to the call, GoodRx will issue a press release containing a link

GoodRx Announces Date for First Quarter 2021 Earnings Release and Conference Call

Skillz

These three growth stocks are down big. The decline in stock price could mean a great buying opportunity for long-term investors.

3 Growth Stocks That Could Be Great Long-Term Investments

GoodRx is a free-to-use platform that sources discounts on prescription drugs for patients in the US. The business is growing its user base, which is powering expansion into telehealth and subscription services.

GoodRx: Understanding This Misunderstood Disruptor

Snowflake

Unity Software

After a handful of companies had their initial public offering (IPO), let's take a deeper look at each of their first quarterly reports. The post These 5 Hot IPOs Post Weak Q4 Results appeared first on InvestorPlace.

These 5 Hot IPOs Post Weak Q4 Results

Some of the drug discounter's growth is out of the company's hands.

Can GoodRx Bounce Back From Its Pandemic Slowdown?

GoodRx Q4 earnings and FY2021 forecast continued to validate the strong core of the company and foreshadowed the future revenue drivers. The primary prescription business is a steady and growing cash cow that provides a strong valuation floor.

GoodRx: A Doctor's Prescription For Your Growth Portfolio

This healthcare tech company has helped consumers save a cumulative $25 billion on prescription drugs. But that doesn't necessarily make its stock a buy.

Could GoodRx Be a Millionaire-Maker Stock?

Poshmark

Lordstown Motors

Investors aren't seeing the results that they'd hoped for from these newcomers to the public markets.

News for GoodRx Holdings Stock (GDRX)